BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 25950896)

  • 41. Participants at the ASCCP 2000 Biennial Meeting adhere to published guidelines in their management of atypical squamous cells and atypical glandular cells on pap test.
    Ancheta E; Perry J; Bernard-Pearl L; Paul S; Darragh T; Smith-McCune K
    J Low Genit Tract Dis; 2003 Oct; 7(4):279-84. PubMed ID: 17051084
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hybrid Capture Human Papillomavirus Testing as an Adjunct to the Follow-Up of Patients with ASCUS and LGSIL Pap Smears: A Study of a Screening Population.
    McLachlin CM; Alanen KW; Elit LM; Smith EA; Kerkvliet NA
    J Low Genit Tract Dis; 2000 Jan; 4(1):12-7. PubMed ID: 25950784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of cytologic follow-up as the recommended management for patients with atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions.
    Alanen KW; Elit LM; Molinaro PA; McLachlin CM
    Cancer; 1998 Feb; 84(1):5-10. PubMed ID: 9500646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HPV DNA testing in the triage of atypical squamous cells of undetermined significance (ASCUS): cost comparison of two methods.
    Layfield LJ; Qureshi MN
    Diagn Cytopathol; 2005 Aug; 33(2):138-43. PubMed ID: 16007672
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS).
    Walker JL; Wang SS; Schiffman M; Solomon D;
    Am J Obstet Gynecol; 2006 Aug; 195(2):341-8. PubMed ID: 16890545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ASCCP Practice Guidelines Management Guidelines for the Follow-up of Atypical Squamous Cells of Undetermined Significance (ASCUS).
    Cox TJ; Wilkinson EJ; Lonky N; Waxman A; Tosh R; Tedeschi C
    J Low Genit Tract Dis; 2000 Apr; 4(2):99-105. PubMed ID: 25950896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atypical squamous and glandular cells of undetermined significance (ASCUS and AGUS) of the uterine cervix.
    Cenci M; Vecchione A
    Anticancer Res; 2000; 20(5C):3701-7. PubMed ID: 11268442
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
    Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
    Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.